Skip to content

Modulating Movement Intention Via Cortical Stimulation

Modulating Movement Intention Via Cortical Stimulation in Healthy Subjects and Patients With Psychogenic Movement Disorders and Non-epileptic Seizures

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03233399
Enrollment
30
Registered
2017-07-28
Start date
2017-07-20
Completion date
2027-05-31
Last updated
2025-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychogenic Movement Disorder, Seizure Disorder, Seizures

Keywords

Electroencephalography, Magnetoencephalography, Transcranial Magnetic Stimulation

Brief summary

The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.

Detailed description

This study will: * Explore effects of TMS and tDCS on movement intention. * Discern the neural activity underlying modulation of movement intention with neuroimaging recording. * Identify brain stimulation's effect in patients with psychogenic tremor and non-epileptic seizures. * Technical development of new experimental paradigms and data analysis methods. * Data collection for hypotheses development.

Interventions

DEVICESham TMS3 stimulation

half of the subjects will receive sham stimulation first

DEVICErTMS of left or right angular gyrus (AG) or frontal cortex (FC)

Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.

DEVICEAnodal tDCS of left or right AG or FC

Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

(Healthy Controls) * Fluent in English (Patients with PMD or PNES): * Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders. * Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening

Exclusion criteria

* Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI * Chronic or progressive medical condition * Any history of traumatic brain injury or significant head trauma * Currently meets criteria for substance abuse or dependence * History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation * Pregnancy * Metal or devices in the head, including neurostimulators or metal foreign bodies * Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS. * Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.). * Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under strong potential hazard list in Rossi et al., 2009 * Current diagnosis of any inflammatory or autoimmune disorder within last 6 months PMD and PNES Patients * Any history of traumatic brain injury or significant head trauma * Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures; * Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s); * Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months * Metal or devices in the head, including neurostimulators or metal foreign bodies * Taking tricyclic antidepressant medications or CNS active drugs under strong potential hazard list in Rossi et al., 2009; * Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24; * Recurrent visual hallucinations, within the past 6 months; * History of significant uncontrollable movements of the head; * Any clinically significant abnormality on vital signs

Design outcomes

Primary

MeasureTime frameDescription
Changes in signal intensity measured during MEG3 Hoursas a result of altering cerebral perfusion in response to neurophysiologic stimulation
Changes in signal intensity measured using of tDCS30 Minutesas a result of altering cerebral perfusion in response to neurophysiologic stimulation
Changes in signal intensity measured during EEG recording3 Hoursas a result of altering cerebral perfusion in response to neurophysiologic stimulation

Countries

United States

Contacts

Primary ContactNalini Jeet
Nalini.Jeet@nyulangone.org(212) 263-0228

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026